These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 32013138)
1. Cerium Oxide Nanoparticles Rescue α-Synuclein-Induced Toxicity in a Yeast Model of Parkinson's Disease. Ruotolo R; De Giorgio G; Minato I; Bianchi MG; Bussolati O; Marmiroli N Nanomaterials (Basel); 2020 Jan; 10(2):. PubMed ID: 32013138 [TBL] [Abstract][Full Text] [Related]
2. Cerium oxide NPs mitigate the amyloid formation of α-synuclein and associated cytotoxicity. Zand Z; Khaki PA; Salihi A; Sharifi M; Qadir Nanakali NM; Alasady AA; Aziz FM; Shahpasand K; Hasan A; Falahati M Int J Nanomedicine; 2019; 14():6989-7000. PubMed ID: 31695369 [TBL] [Abstract][Full Text] [Related]
3. Cerium oxide nanoparticles modulating the Parkinson's disease conditions: From the alpha synuclein structural point of view and antioxidant properties of cerium oxide nanoparticles. Yao X; Guan Y; Wang J; Wang D Heliyon; 2024 Jan; 10(1):e21789. PubMed ID: 38163101 [TBL] [Abstract][Full Text] [Related]
4. Size-Dependent Cytotoxicity and Reactive Oxygen Species of Cerium Oxide Nanoparticles in Human Retinal Pigment Epithelia Cells. Ma Y; Li P; Zhao L; Liu J; Yu J; Huang Y; Zhu Y; Li Z; Zhao R; Hua S; Zhu Y; Zhang Z Int J Nanomedicine; 2021; 16():5333-5341. PubMed ID: 34408413 [TBL] [Abstract][Full Text] [Related]
6. The acute pulmonary and thrombotic effects of cerium oxide nanoparticles after intratracheal instillation in mice. Nemmar A; Al-Salam S; Beegam S; Yuvaraju P; Ali BH Int J Nanomedicine; 2017; 12():2913-2922. PubMed ID: 28435267 [TBL] [Abstract][Full Text] [Related]
7. Interaction of Alpha-Synuclein With Lipids: Mitochondrial Cardiolipin as a Critical Player in the Pathogenesis of Parkinson's Disease. Gilmozzi V; Gentile G; Castelo Rueda MP; Hicks AA; Pramstaller PP; Zanon A; Lévesque M; Pichler I Front Neurosci; 2020; 14():578993. PubMed ID: 33122994 [TBL] [Abstract][Full Text] [Related]
8. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease. Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897 [TBL] [Abstract][Full Text] [Related]
9. Cytotoxicity of CeO Sendra M; Volland M; Balbi T; Fabbri R; Yeste MP; Gatica JM; Canesi L; Blasco J Aquat Toxicol; 2018 Jul; 200():13-20. PubMed ID: 29704629 [TBL] [Abstract][Full Text] [Related]
10. Study of wild-type α-synuclein binding and orientation on gold nanoparticles. Yang JA; Johnson BJ; Wu S; Woods WS; George JM; Murphy CJ Langmuir; 2013 Apr; 29(14):4603-15. PubMed ID: 23477540 [TBL] [Abstract][Full Text] [Related]
11. Advances in the Study of Cerium Oxide Nanoparticles: New Insights into Antiamyloidogenic Activity. Siposova K; Huntosova V; Shlapa Y; Lenkavska L; Macajova M; Belous A; Musatov A ACS Appl Bio Mater; 2019 May; 2(5):1884-1896. PubMed ID: 35030678 [TBL] [Abstract][Full Text] [Related]
12. Study of Biological Behavior and Antimicrobial Properties of Cerium Oxide Nanoparticles. Chatzimentor I; Tsamesidis I; Ioannou ME; Pouroutzidou GK; Beketova A; Giourieva V; Papi R; Kontonasaki E Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896269 [TBL] [Abstract][Full Text] [Related]
13. The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Gitler AD; Bevis BJ; Shorter J; Strathearn KE; Hamamichi S; Su LJ; Caldwell KA; Caldwell GA; Rochet JC; McCaffery JM; Barlowe C; Lindquist S Proc Natl Acad Sci U S A; 2008 Jan; 105(1):145-50. PubMed ID: 18162536 [TBL] [Abstract][Full Text] [Related]
14. α-Synuclein: membrane interactions and toxicity in Parkinson's disease. Auluck PK; Caraveo G; Lindquist S Annu Rev Cell Dev Biol; 2010; 26():211-33. PubMed ID: 20500090 [TBL] [Abstract][Full Text] [Related]
15. Increased Lysosomal Exocytosis Induced by Lysosomal Ca Tsunemi T; Perez-Rosello T; Ishiguro Y; Yoroisaka A; Jeon S; Hamada K; Rammonhan M; Wong YC; Xie Z; Akamatsu W; Mazzulli JR; Surmeier DJ; Hattori N; Krainc D J Neurosci; 2019 Jul; 39(29):5760-5772. PubMed ID: 31097622 [TBL] [Abstract][Full Text] [Related]
16. Polyethylenimine-associated cerium oxide nanoparticles: A novel promising gene delivery vector. Hasanzadeh L; Darroudi M; Ramezanian N; Zamani P; Aghaee-Bakhtiari SH; Nourmohammadi E; Kazemi Oskuee R Life Sci; 2019 Sep; 232():116661. PubMed ID: 31323272 [TBL] [Abstract][Full Text] [Related]
17. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons. Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146 [TBL] [Abstract][Full Text] [Related]
18. Cerium oxide nanoparticles are more toxic than equimolar bulk cerium oxide in Caenorhabditis elegans. Arnold MC; Badireddy AR; Wiesner MR; Di Giulio RT; Meyer JN Arch Environ Contam Toxicol; 2013 Aug; 65(2):224-33. PubMed ID: 23619766 [TBL] [Abstract][Full Text] [Related]
19. Binding of Noradrenaline to Native and Intermediate States during the Fibrillation of α-Synuclein Leads to the Formation of Stable and Structured Cytotoxic Species. Singh P; Bhat R ACS Chem Neurosci; 2019 Jun; 10(6):2741-2755. PubMed ID: 30917654 [TBL] [Abstract][Full Text] [Related]
20. α-Syn oligomers incubated with Parkinson's disease plasma promote neuron damage. Yang W; Li X; Yin N Int J Clin Exp Pathol; 2020; 13(8):1995-2008. PubMed ID: 32922594 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]